
Annual report 2025
added 02-27-2026
Inogen Cash Flow 2011-2026 | INGN
Annual Cash Flow Inogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-11.2 M | 5.91 M | -3.23 M | -37.5 M | 23.6 M | 37 M | 40.6 M | 60 M | 60.5 M | 31 M | - | - | - | - | - |
Depreciation & Amortization |
20.7 M | 21 M | 18.2 M | 23.5 M | 21.6 M | 18.6 M | 13.8 M | 11.3 M | 12.3 M | 13.6 M | 14 M | 12.1 M | 8.54 M | 4.98 M | 298 K |
Accounts Payables |
20.3 M | 16.6 M | 13.5 M | 18.2 M | 10.3 M | 12.5 M | 16.4 M | 13.7 M | 9.54 M | 5.74 M | 7.45 M | - | - | - | - |
Accounts Receivables |
38.9 M | 29.6 M | 42.2 M | 62.7 M | 24.5 M | 29.7 M | 34.3 M | 37 M | 31.4 M | 30.8 M | 19.9 M | 19.3 M | - | - | - |
Total Inventories |
26 M | 24.8 M | 21.8 M | 34.1 M | 31.9 M | 24.8 M | 35.7 M | 27.1 M | 18.8 M | 14.3 M | 8.65 M | 7.62 M | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Inogen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -16.8 M | - | - | - | -4.75 M | - | - | - | -6.3 M | - | -22 M | - | -18.1 M | - | 17.1 M | - | 2.86 M | - | 20.8 M | 14.1 M | 540 K | - | 31.2 M | 16.6 M | -1.82 M | - | 47.6 M | 33.3 M | 12.2 M | - | 47.5 M | 30.1 M | - | - | - | - | - | - | - | - | - | - | - | - | -1.33 M | - | - | 6.88 M | 2.69 M | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
3.93 M | 4.01 M | 5.19 M | - | 4.21 M | 4.16 M | 5.26 M | - | 4.41 M | 4.26 M | 4.09 M | - | 3.78 M | 3.7 M | 5.76 M | - | 15.9 M | 3.04 M | 5.1 M | - | 13.7 M | 8.94 M | 4.46 M | - | 9.22 M | 5.55 M | 2.79 M | - | 8.52 M | 5.81 M | 2.99 M | - | 9.26 M | 6.32 M | 3.2 M | - | 10.3 M | 6.87 M | 3.45 M | - | 10.5 M | 6.91 M | 3.44 M | - | 8.78 M | 5.59 M | 2.66 M | - | 6 M | 3.65 M | 1.66 M | - | - | - | - | - | - | - | - |
Accounts Payables |
21.2 M | 21.9 M | 23.3 M | 16.6 M | 15.5 M | 15 M | 15.9 M | 13.5 M | 15.4 M | 13.4 M | 18 M | 18.2 M | 21.5 M | - | 18.1 M | 10.3 M | 15.9 M | 15.6 M | 14.6 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 9.54 M | 9.54 M | 9.54 M | 9.54 M | 5.74 M | 5.74 M | 5.74 M | 5.74 M | 7.45 M | 7.45 M | 7.45 M | 7.45 M | 6.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
40.4 M | 38.6 M | 36.6 M | 29.6 M | 34.2 M | 36 M | 40.2 M | 42.2 M | 48.4 M | 51.1 M | 53.9 M | 62.7 M | 50.5 M | - | 34 M | 24.5 M | 32.9 M | 36.9 M | 38.4 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 37 M | 37 M | 37 M | 37 M | 31.4 M | 31.4 M | 34.8 M | 31.4 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | - | - | - | - | - | - | - | - |
Total Inventories |
25.1 M | 24.3 M | 26.3 M | 24.8 M | 23.3 M | 24 M | 24.6 M | 21.8 M | 24 M | 30.7 M | 38.8 M | 34.1 M | 35.7 M | - | 34.1 M | 31.9 M | 31.8 M | 27.2 M | 26.4 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 35.7 M | 35.7 M | 35.7 M | 35.7 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 8.65 M | 8.65 M | 8.65 M | 8.65 M | 7.62 M | 7.62 M | 7.62 M | 7.62 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Inogen, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Sensus Healthcare
SRTS
|
$ 4.1 | -2.96 % | $ 66.9 M | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 9.86 | 3.25 % | $ 759 M | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Delcath Systems
DCTH
|
$ 9.18 | -0.22 % | $ 329 M | ||
|
Stryker Corporation
SYK
|
$ 335.31 | 2.37 % | $ 128 B | ||
|
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
TELA Bio
TELA
|
$ 0.71 | 3.13 % | $ 33.3 M | ||
|
CONMED Corporation
CNMD
|
$ 36.91 | -0.32 % | $ 1.15 B | ||
|
Insulet Corporation
PODD
|
$ 220.63 | 2.14 % | $ 15.5 B | ||
|
Tandem Diabetes Care
TNDM
|
$ 23.46 | -3.32 % | $ 1.6 B | ||
|
Electromed
ELMD
|
$ 24.74 | 0.32 % | $ 209 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.62 | -8.39 % | $ 33.7 M | ||
|
Aethlon Medical
AEMD
|
$ 2.37 | 2.22 % | $ 3.7 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Smith & Nephew plc
SNN
|
$ 32.45 | - | $ 23.8 B | ||
|
LivaNova PLC
LIVN
|
$ 64.75 | 2.28 % | $ 3.53 B | ||
|
InspireMD
NSPR
|
$ 1.74 | -0.57 % | $ 112 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 11.6 | 1.84 % | $ 1.57 B | ||
|
Penumbra
PEN
|
$ 337.13 | 0.26 % | $ 13.1 B | ||
|
MiMedx Group
MDXG
|
$ 4.08 | -0.49 % | $ 603 M | ||
|
Invacare Corporation
IVC
|
- | - | $ 24.7 M | ||
|
Viemed Healthcare
VMD
|
$ 9.32 | -0.32 % | $ 363 M | ||
|
Myomo
MYO
|
$ 0.69 | -1.61 % | $ 28.9 M | ||
|
NanoVibronix
NAOV
|
- | - | $ 1.08 M | ||
|
Varex Imaging Corporation
VREX
|
$ 10.72 | 0.28 % | $ 444 M | ||
|
Vivos Therapeutics
VVOS
|
$ 1.24 | 7.37 % | $ 6.22 M | ||
|
Inspire Medical Systems
INSP
|
$ 51.41 | - | $ 1.51 B | ||
|
Pulmonx Corporation
LUNG
|
$ 1.29 | -1.15 % | $ 52.5 M | ||
|
Beyond Air
XAIR
|
$ 0.74 | 0.01 % | $ 50.1 M | ||
|
Xtant Medical Holdings
XTNT
|
$ 0.57 | 0.85 % | $ 76.2 M |